Publications by authors named "H Billett"
: Immune thrombocytopenia (ITP) is an acquired autoimmune disorder affecting patients of all ages and backgrounds. While current standards favor medical therapy in the frontline setting, splenectomy remains an integral part of treatment in refractory cases. Ideal parameters for patient selection for surgery remain elusive.
View Article and Find Full Text PDFThe pathophysiology of immune thrombocytopenia (ITP) involves immune-mediated platelet destruction. The presence of adipose tissue in obese individuals creates an inflammatory environment that could potentially impact the clinical course and outcomes of ITP. However the relationship between obesity and ITP outcomes has not been well described.
View Article and Find Full Text PDFArticle Synopsis
- The study examined whether reducing the dose of apixaban from 5 mg to 2.5 mg twice daily is safe for patients with cancer-associated venous thromboembolism (VTE) who have already undergone 6-12 months of anticoagulation therapy.
- In a trial involving 360 cancer patients, the incidence of major and clinically relevant nonmajor bleeding was similar between the 2.5 mg and 5 mg groups, with rates of 8.9% and 12.2%, respectively.
- The findings suggest that reducing the dose of apixaban does not significantly affect bleeding risks, recurrent VTE, or mortality rates in cancer patients, indicating that the
Article Synopsis
- * A study surveyed hematology practitioners to see how they handle thromboprophylaxis for sickle cell patients before and during the COVID-19 pandemic.
- * Results showed that most adult doctors recommend preventive treatments, while fewer pediatricians do the same, although recommendations for both groups increased during the pandemic.